Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Last traded Jun 15, 2026. This price is not current.
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Assertio Holdings, Inc.
How ASRT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-09-09 | Rolvedon (eflapegrastim-xnst) | PDUFA Date Approved | PDUFA |
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ROLVEDON | |||
| INDOCIN products | |||
| Sympazan | |||
| SPRIX |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eflapegrastim Small MoleculesNCT04570423 | Solid Tumors | Phase 2 | RECRUITING | 40 | Oct 1, 2027 | ||||||
| Eflapegrastim BiologicsMarketedNCT04187898 | Neutropenia | Approved | COMPLETED | 59 | Aug 16, 2024 | ||||||
| SPI-2012 Small MoleculesMarketedNCT01724866 | Neutropenia | Approved | COMPLETED | 791 | Aug 12, 2014 |
Readouts, endpoints and source filings for every ASRT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mason Heather LDirector | Disposition | -6,666 20,944 held | $0.00 | 05/13/2026 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.7 % (133.3 %) | 5.06 M | 265.71 K | -6.77% ( -19.29 K) |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How ASRT ranks across every disease it competes in